TY - JOUR
T1 - Diagnostic techniques and therapeutic challenges in patients with TP53 dysfunctional chronic lymphocytic leukemia
AU - Best, Giles
AU - Thompson, Philip
AU - Tam, Constantine S.
PY - 2012/11
Y1 - 2012/11
N2 - Aberrations of the TP53 pathway, whether by deletion or mutation, are increasingly recognized as one of the most important biological risk factors in chronic lymphocytic leukemia. Yet, there is little consensus on how to assess for TP53 defects in the clinic, and very few clinical studies to guide optimal management of such patients. In this review, we discuss the state-of-the-art in the assessment of the TP53 pathway, and review the evidence-base for therapeutic recommendations.
AB - Aberrations of the TP53 pathway, whether by deletion or mutation, are increasingly recognized as one of the most important biological risk factors in chronic lymphocytic leukemia. Yet, there is little consensus on how to assess for TP53 defects in the clinic, and very few clinical studies to guide optimal management of such patients. In this review, we discuss the state-of-the-art in the assessment of the TP53 pathway, and review the evidence-base for therapeutic recommendations.
KW - 17p deletion
KW - Fludarabine
KW - fluorescence in situ hybridization
KW - rituximab
UR - http://www.scopus.com/inward/record.url?scp=84867188772&partnerID=8YFLogxK
U2 - 10.3109/10428194.2012.692088
DO - 10.3109/10428194.2012.692088
M3 - Review article
C2 - 22568511
AN - SCOPUS:84867188772
SN - 1042-8194
VL - 53
SP - 2105
EP - 2115
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 11
ER -
